SLC5A2 and type 2 diabetes mellitus: Although studies of type 1 and type 2 diabetes have shown substantial incremental benefit of different SGLT2 inhibitors on fasting glucose values,[6–8, 23–27] most studies have implied that a fundamental effect of SGLT2 inhibition is the attenuation of post-prandial glucose excursions.[28, 29] The use of the CGM-based AGP in the current study afforded a unique opportunity to explore these diurnal patterns among a cohort of patients with a range of baseline HbA1c from target levels as low as 6.5%.